clinical trial · NCT05370235
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Clinuvel Europe Limited·phase2·unknown·n = 6
Xeroderma PigmentosumAfamelanotide
brief summary
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
started
Mar 28, 2022
primary completion
Jun 1, 2024
completion
Dec 1, 2024
last updated
Sep 21, 2023
official title
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol